Skip to main content
. 2009 Jul;50(7):1479–1486. doi: 10.1194/jlr.P900014-JLR200

TABLE 2.

Case-control analyses for associations with obesity and metabolic syndrome components in Chinese Hans with the criteria of NCEP ATP III for Asian-Americans

Beijing
 Shanghai
 Beijing + Shanghai
Total number Case (MAF) OR (95% CI) P Case (MAF) OR (95% CI) P OR (95% CI) P P(heter)
RBP4-metabolic syndrome components
 Obesity 1989 320 1.34 (1.17 − 1.53) 2.07E-5 154 1.48 (1.23 − 1.76) 1.91E-5 1.38 (1.24 − 1.54) 4.08E-9
 Central obesity 3210 867 1.31 (1.18 − 1.45) 3.28E-7 664 1.41 (1.26 − 1.58) 1.21E-9 1.35 (1.25 − 1.45) 1.15E-14
 Hypertriglyceridemia 3210 423 1.62 (1.44 − 1.82) 6.50E-16 354 2.06 (1.79 − 2.36) 1.25E-24 1.80 (1.64 − 1.96) 2.53E-38
 Low HDL-C 3210 621 1.08 (0.97 − 1.20) 0.19 721 1.16 (1.03 − 1.30) 0.0122 1.11 (1.03 − 1.21) 0.0066
 Hyperglycemia 3210 851 1.00 (0.91 − 1.10) 0.99 451 1.05 (0.94 − 1.19) 0.39 1.02 (0.95 − 1.10)) 0.56
 Hypertension 3210 1188 1.19 (1.06 − 1.35) 0.0043 1033 1.17 (1.04 − 1.32) 0.0111 1.18 (1.08 − 1.28) 0.0001
RBP4-metabolic syndrome components
rs10882273 (+11880 T>C)a
 Obesity 315 (0.17) 1.12 (0.85 − 1.47) 0.42 151 (0.13) 1.03 (0.72 − 1.47) 0.87 1.08 (0.87 − 1.35) 0.46 0.72
 Central obesity 853 (0.17) 1.03 (0.85 − 1.26) 0.75 643 (0.13) 1.06 (0.86 − 1.32) 0.58 1.05 (0.90 − 1.21) 0.54 0.85
 Hypertriglyceridemia 416 (0.17) 1.03 (0.82 − 1.28) 0.82 346 (0.13) 1.06 (0.82 − 1.37) 0.64 1.04 (0.88 − 1.23) 0.63 0.84
 Low HDL-C 607 (0.17) 1.02 (0.82 − 1.26) 0.87 703 (0.13) 0.92 (0.73 − 1.15) 0.45 0.97 (0.83 − 1.13) 0.69 0.51
 Hyperglycemia 836 (0.17) 1.00 (0.82 − 1.21) 0.96 432 (0.12) 0.85 (0.66 − 1.08) 0.19 0.94 (0.80 − 1.09) 0.39 0.32
 Hypertension 1166 (0.17) 1.06 (0.84 − 1.35) 0.63 998 (0.13) 0.92 (0.73 − 1.15) 0.45 0.98 (0.83 − 1.16) 0.83 0.38
rs3758539 (-803 G>A)a
 Obesity 317 (0.15) 1.23 (0.93 − 1.63) 0.16 145 (0.11) 1.13 (0.77 − 1.66) 0.53 1.19 (0.95 − 1.50) 0.13 0.74
 Central obesity 858 (0.14) 1.05 (0.85 − 1.31) 0.63 634 (0.11) 1.12 (0.88 − 1.42) 0.36 1.08 (0.92 − 1.27) 0.33 0.71
 Hypertriglyceridemia 421 (0.13) 0.90 (0.70 − 1.14) 0.37 336 (0.11) 1.05 (0.79 − 1.39) 0.75 0.96 (0.80 − 1.15) 0.96 0.41
 Low HDL-C 613 (0.14) 0.92 (0.74 − 1.16) 0.49 686 (0.10) 0.97 (0.76 − 1.25) 0.83 0.94 (0.80 − 1.12) 0.51 0.76
 Hyperglycemia 841 (0.14) 1.02 (0.82 − 1.25) 0.88 437 (0.09) 0.94 (0.72 − 1.22) 0.63 0.98 (0.94 − 1.16) 0.85 0.65
 Hypertension 1170 (0.14) 1.03 (0.80 − 1.33) 0.84 986 (0.10) 0.93 (0.73 − 1.20) 0.59 0.98 (0.82 − 1.17) 0.81 0.60
rs3758538 (-1265 A>C)b
 Obesity 300 (0.06) 0.90 (0.58 − 1.40) 0.64 142 (0.05) 0.97 (0.53 − 1.75) 0.91 0.94 (0.66 − 1.35) 0.74 0.85
 Central obesity 814 (0.06) 0.85 (0.61 − 1.19) 0.35 626 (0.05) 0.83 (0.58 − 1.19) 0.32 0.86 (0.67 − 1.09) 0.21 0.93
 Hypertriglyceridemia 395 (0.04) 0.65 (0.43 − 0.97) 0.0372 341 (0.04) 0.60 (0.37 − 0.96) 0.0325 0.62 (0.45 − 0.85) 0.0026 0.80
 Low HDL-C 577 (0.06) 0.76 (0.54 − 1.11) 0.17 683 (0.05) 0.81 (0.56 − 1.17) 0.26 0.79 (0.61 − 1.02) 0.07 0.86
 Hyperglycemia 797 (0.06) 1.07 (0.77 − 1.48) 0.70 434 (0.04) 0.81 (0.54 − 1.21) 0.31 0.96 (0.74 − 1.23) 0.72 0.30
 Hypertension 1112 (0.06) 0.87 (0.59 − 1.28) 0.49 980 (0.05) 0.98 (0.68 − 1.41) 0.91 0.93 (0.71 − 1.22) 0.61 0.67
rs17108993 (-3248 C>G)a,b
 Obesity 314 (0.05) 0.93 (0.59 − 1.47) 0.77 152 (0.04) 0.56 (0.30 − 1.05) 0.07 0.78 (0.54 − 1.13) 0.19 0.20
 Central obesity 854 (0.05) 0.95 (0.67 − 1.34) 0.77 657 (0.06) 0.88 (0.65 − 1.20) 0.41 0.91 (0.72 − 1.15) 0.42 0.74
 Hypertriglyceridemia 412 (0.05) 1.07 (0.73 − 1.58) 0.73 352 (0.06) 0.99 (0.68 − 1.43) 0.94 1.03 (0.78 − 1.34) 0.86 0.76
 Low HDL-C 606 (0.05) 0.97 (0.67 − 1.41) 0.88 712 (0.06) 1.14 (0.83 − 1.56) 0.42 1.07 (0.84 − 1.35) 0.60 0.53
 Hyperglycemia 834 (0.05) 0.93 (0.66 − 1.31) 0.68 447 (0.06) 0.89 (0.63 − 1.25) 0.49 0.91 (0.71 − 1.16) 0.44 0.84
 Hypertension 1164 (0.05) 0.97 (0.65 − 1.46) 0.89 1022 (0.06) 0.68 (0.50 − 0.94) 0.0185 0.78 (0.61 − 1.00) 0.05 0.18
rs11187549 (-3839 G>A)
 Obesity 304 (0.50) 1.05 (0.86 − 1.28) 0.64 152 (0.45) 0.84 (0.66 − 1.08) 0.18 0.96 (0.82 − 1.13) 0.63 0.18
 Central obesity 833 (0.49) 1.04 (0.89 − 1.20) 0.64 642 (0.47) 0.93 (0.81 − 1.08) 0.33 0.98 (0.88 − 1.09) 0.68 0.31
 Hypertriglyceridemia 403 (0.49) 1.04 (0.88 − 1.23) 0.65 347 (0.46) 0.96 (0.81 − 1.14) 0.65 1.00 (0.89 − 1.13) 0.98 0.52
 Low HDL-C 598 (0.48) 0.95 (0.82 − 1.16) 0.55 699 (0.48) 0.98 (0.84 − 1.13) 0.76 0.97 (0.87 − 1.08) 0.52 0.83
 Hyperglycemia 810 (0.48) 0.98 (0.85 − 1.13) 0.77 440 (0.46) 0.97 (0.83 − 1.13) 0.69 0.97 (0.87 − 1.08) 0.56 0.92
 Hypertension 1146 (0.47) 0.88 (0.74 − 1.05) 0.17 1004 (0.47) 0.94 (0.80 − 1.09) 0.41 0.91 (0.81 − 1.02) 0.11 0.62

BMI, body mass index; RBP4, retinol-binding protein 4. Obesity and normal weight were defined as BMI ⩾ 28 kg/m2 and BMI < 24 kg/m2 according to Chinese criteria. Overweight participants (n = 1221, 24 kg/m2 ⩽ BMI < 28 kg/m2) were excluded from the analyses for obesity. The metabolic syndromes was defined by the updated National Cholesterol Education Program Adult Treatment Panel III criteria (NCEP-ATP III) for Asian-Americans: (1) waist circumference ⩾ 90 cm (men); ⩾ 80 cm (women); (2) triglycerides ⩾ 1.7 mmol/L; (3) HDL-C < 1.03 mmol/L (men); < 1.30 mmol/L (women); (4) fasting plasma ⩾ 5.6 mmol/L or previously diagnosed type 2 diabetes or oral anti-diabetic medication; (5) blood pressure ⩾ 130 / 85 mm Hg or current use of anti-hypertensive drugs. P values were adjusted for age, sex, and BMI (where appropriate).

a

When Beijing and Shanghai participants combined, meta-analyses were conducted to evaluate the combined effects size for SNPs with significant differences in genotype distribution. Otherwise, analyses were performed by pooling all 3,210 subjects together.

b

Dominant model was applied. Otherwise, additive model was used.